Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 18/20 | 0.51 |
| ▸ | PTPN2 | P17706 | 4/20 | 0.51 |
| ▸ | PTPRC | P08575 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3729935 | 1.00 | PTPN1 (0.51) | PTPN1PTPN2PTPRCMAPT | |
| SCHEMBL4001887 | 0.91 | PTPN1 (0.50) | PTPN1PTPN2PTPRCMAPT | |
| SCHEMBL3737621 | 0.88 | PTPN1 (0.52) | PTPN1PTPN2PTPRC | |
| SCHEMBL29758794 | 0.88 | PTPN1 (0.52) | PTPN1PTPN2PTPRC | |
| SCHEMBL3735601 | 0.87 | PTPN1 (0.50) | PTPN1PTPN2PTPRC | |
| SCHEMBL4863123 | 0.78 | F10 (0.38) | MAPT | |
| SCHEMBL4863118 | 0.78 | MMP9 (0.38) | PTPN1PTPN2 | |
| SCHEMBL3739161 | 0.77 | PTPN1 (0.42) | PTPN1PTPN2MAPT | |
| SCHEMBL3735632 | 0.76 | PTPN1 (0.39) | PTPN1PTPN2 | |
| SCHEMBL27715841 | 0.74 | PTPN1 (0.60) | PTPN1PTPN2PTPRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11660306-B2 | Treatment of Rett syndrome | COLD SPRING HARBOR LABORATORY (US) | 2023-05-30 | — | — | US | disclosed |
| US-20190247408-A1 | TREATMENT OF RETT SYNDROME | COLD SPRING HARBOR LABORATORY (US) | 2019-08-15 | — | — | US | disclosed |
| US-20170296561-A1 | TREATMENT OF RETT SYNDROME | COLD SPRING HARBOR LABORATORY | 2017-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190247408-A1 | TREATMENT OF RETT SYNDROME | MECP2, BDNF, NTRK2 | PTPN1 4223/4885PTPN2 3963/4885PTPRC 2835/4885 |
| US-11660306-B2 | Treatment of Rett syndrome | MECP2, BDNF, NTRK2 | PTPN1 4223/4885PTPN2 3963/4885PTPRC 2835/4885 |
| US-20170296561-A1 | TREATMENT OF RETT SYNDROME | MECP2, BDNF, GRIN2A | PTPN1 3602/4885PTPN2 3321/4885PTPRC 1797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.